Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 116

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 6
Chunk 116
---
 with the Corporations Act, we have entered
into standard deeds of indemnity agreements with each of our directors pursuant to which we indemnify each director against certain liabilities
incurred as a director or officer, including costs and expenses associated in successfully defending legal proceedings and maintain directors’
and officers’ insurance cover in favor of the respective directors for seven years after they cease to be directors.

D. Employees

As of June 30, 2025, we had
14 employees. Of these employees, 13 were employed in research and development and 1 in general management and administration. As of June
30, 2025, 1 employee was employed in the United Kingdom, 1 employee was employed in Australia and 12 employees were employed in the United
States.

Each of our full-time employees
has entered into an agreement with an unlimited term. We may only terminate the employment of any of our employees in accordance with
the relevant employee’s contract of employment.

Our standard contract of employment
for full-time employees provides that we can terminate the employment of an employee without notice for serious misconduct or with between
one to six months’ notice without cause (as set out in the relevant employee’s contract of employment).

E. Share Ownership

For a description of arrangements
involving the employees in the capital of the Company, including any arrangement that involves the issue or grant of options or shares
or securities of the Company, see “ Item 6. Directors, Senior Management and Employees - B. Compensation - “ Employee
Share Option Plan” and “ Performance Rights Plan.”

Ownership of Senior Management and Directors

The following table sets forth
certain information as of June 30, 2025, regarding the ownership of our ordinary shares by each of our directors and senior management
and by all of our directors and senior management as a group. The percentages shown are based on 2,364,949,502 ordinary shares issued
and outstanding as of June 30, 2025.

  Name                                                                                      
 ────────────────────────────────────────────────────────────────────────────────────────────
  Riccardo Canevari                                                   21,179,986      *     
  Paul Hopper (1)                                                    147,721,428      6.25  
  Ian Turner                                                           9,255,292      *     
  Hester Larkin                                                          644,247      *     
  Leila Alland                                                         1,071,740      *     
  Phillip Hains                                                       15,